Reading HALO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HALO free→Reading HALO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HALO free→NASDAQHealth CareBiotechnologySnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but the sector backdrop is a headwind, which may impact future results. Earnings quality is neutral, and management's recent track record has been fairly steady, with a capital-friendly approach. Peer multiples imply a price about 14% above where it trades (it looks cheap on this basis); the read is fair. Watching for guidance changes from HALO and sector trends among bellwethers like VRTX, REGN, and ARGX will be important for future performance. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $69.50. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $70 HALO trades at 16× p/e, in line with its 16× p/e peer median. Our $87 fair value reflects that, high confidence. Analysts: $75–$96. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 20% below a flat-multiple fair value, below our forecast of about 36%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.94x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.82 → $1.82 (-0.0% / 30d). 2 raised, 3 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 60% of analysts rate Buy.
1 PT revisions / 30d. Avg target 30.9% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$118.
How much price usually moves either way.
On a bad day, this stock has moved -$282.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,413.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Better cash flow from operations helps Halozyme grow and spend money wisely. This is important for future investments.
Confirms:Cash from operations was higher than last quarter.
Disproves:Cash from operations is lower than last quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for HALO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$75.00 – $96.00 (median $93.50) · 6 analysts · as of 2026-06-03
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
HALO Halozyme | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
ABBV AbbVie | Above typical Show detailsSector percentile: 79 of 100 | full | low |
AMGN Amgen | Above typical Show detailsSector percentile: 75 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 96 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 82 of 100 | expensive | moderate |
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on achieving significant revenue growth through strategic initiatives.
Improve operating income through cost management and efficiency.
Enhance cash flow from operations to support growth and investment.
Why it matters: The new CFO's strategy could impact financial performance. Investors will watch for changes in financial guidance.
Confirms one read:The market reacted well after the CFO change was announced.
Confirms the other:The market reacted poorly after the CFO change was announced.
Why it matters: Better operating income means Halozyme is controlling costs well. This is important for making money long-term.
Confirms:Operating income increases by more than 10% in Q2 compared to Q1.
Disproves:Operating income does not improve or declines in Q2 compared to Q1.
Why it matters: A drop below 10% would signal a slowdown in revenue growth for Halozyme. This could impact investor confidence in the company's future.
Confirms:Q2 revenue growth reported below 10% year over year.
Disproves:Q2 revenue growth remains at or above 10% year over year.
Why it matters: Updates from the new CFO could signal changes in financial strategy. This may impact revenue and operating income.
Confirms:A press release or statement about new money plans from the CFO.
Disproves:No significant updates or changes in strategy from the CFO in the next quarter.
CFO — Darren Snellgrove: The company hired a new CFO from an external source.